A new Australian study led by Professor Susan Clark from Sydney's Garvan Institute of Medical Research shows that large regions of the genome -- amounting to roughly 2% -- are epigenetically activated in prostate cancer. Regions activated contain many prostate cancer-specific genes, including PSA (prostate specific antigen) and PCA3, the most common prostate cancer markers. Until now, these genes were not known to be regulated epigenetically.